|
|
 Previous Article | Table of Contents | Next Article 
The L4F3 antigen is expressed by unipotent and multipotent colony- forming
cells but not by their precursors
RG Andrews, M Takahashi, GM Segal, JS Powell, ID Bernstein and JW Singer
Antibody L4F3 is a murine monoclonal antibody that recognizes an antigen
expressed on in vitro colony-forming cells, including virtually all CFU-GM,
CFU-Meg, BFU-E, and CFU-Mix. In the present study we examined whether cells
that do not express the L4F3 antigen include precursors of hematopoietic
colony-forming cells. Colony-forming cells were depleted from marrow by
treatment with L4F3 and complement. The remaining cells generated CFU-GM,
BFU-E, and CFU-Mix when cultured in the presence of irradiated adherent
cell layers from long-term marrow cultures. Marrow cells not expressing the
L4F3 antigen, which were separated by cell-sorting techniques, were
depleted of colony-forming cells but nevertheless generated CFU-GM when
cultured over irradiated adherent cell layers. These data suggest that
there are marrow precursors that do not express the L4F3 antigen and that
give rise to colony-forming cells of multiple types. Negative selection
techniques should allow the enrichment of these precursors of
colony-forming cells, thereby enabling direct studies of these immature
stem cells.
Volume 68,
Issue 5,
pp. 1030-1035,
11/01/1986
Copyright © 1986 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. C. Taussig, D. J. Pearce, C. Simpson, A. Z. Rohatiner, T. A. Lister, G. Kelly, J. L. Luongo, G.-a. H. Danet-Desnoyers, and D. Bonnet
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
Blood,
December 15, 2005;
106(13):
4086 - 4092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Walter, B. W. Raden, D. M. Kamikura, J. A. Cooper, and I. D. Bernstein
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
Blood,
February 1, 2005;
105(3):
1295 - 1302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Jurcic, S. M. Larson, G. Sgouros, M. R. McDevitt, R. D. Finn, C. R. Divgi, A. M. Ballangrud, K. A. Hamacher, D. Ma, J. L. Humm, et al.
Targeted alpha particle immunotherapy for myeloid leukemia
Blood,
July 30, 2002;
100(4):
1233 - 1239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Jurcic, T. DeBlasio, L. Dumont, T.-J. Yao, and D. A. Scheinberg
Molecular Remission Induction with Retinoic Acid and Anti-CD33 Monoclonal Antibody HuM195 in Acute Promyelocytic Leukemia
Clin. Cancer Res.,
February 1, 2000;
6(2):
372 - 380.
[Abstract]
[Full Text]
|
|
|
|
|
